[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"st-elevation-myocardial-infarction-stemi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:st-elevation-myocardial-infarction-stemi":115},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,76,102,129,156,179,204,233,271,294,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620758","impact-of-pre-hospital-heparin-loading-in-stemi-patients-for-primary-pci-the-help-pci-2-trial-100620758",false,"NCT07361783","Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial","The Impact of Injection of a Loading Dose of Unfractionated Heparin on Patients With Acute ST-segment Elevation Myocardial Infarction Scheduled for Primary PCI at Initial Medical Contact: A Multicenter, Prospective, Randomized Controlled Study（HELP-PCI 2）","HELP-PCI-2","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. STEMI within 12 hours of onset Newly developed adjacent two or more leads with ST segment elevation of ≥1mm (lead V2-V3 elevation of ≥2mm).\n\n   Newly developed left bundle branch block (LBBB). In the right bundle-branch block (RBBB), the ST segment of leads V1-V3 is elevated or Q waves occur.\n3. Primary PCI was planned if the time from first medical contact to balloon dilatation was expected to be less than 120 minutes.\n\nExclusion Criteria:\n\n1. Thrombolytic therapy recipients;\n2. Currently taking oral anticoagulant drugs or having been treated with heparin, low molecular weight heparin, suldaparinol sodium, bivalirudin or IIb\u002FIIIa receptor antagonists within 48 hours before randomization;\n3. Patients undergoing cardiopulmonary resuscitation;\n4. Patients with cardiogenic shock;\n5. Combined mechanical complications (rupture of the free wall of the heart, perforation of the ventricular septum, insufficiency or rupture of the papillary muscle leading to severe mitral regurgitation);\n6. History of intracranial parenchymal aneurysm, intracranial arteriovenous malformation, intracranial hemorrhage, ischemic stroke or transient ischemic attack within the last 6 months, and active hemorrhage within the last 2 weeks;\n7. Major surgery within one month;\n8. Previous history of CABG;\n9. Patients with a history of heparin-induced thrombocytopenia or those known to be allergic to anticoagulant or antiplatelet drugs;\n10. Combined with other serious diseases and life expectancy less than 12 months;\n11. Pregnant or lactating women;\n12. Currently participating in clinical research on other drugs or devices;\n13. Refuse to sign the informed consent form;\n14. The researcher judged that it was not suitable to participate in this study.","ALL","18 Years",{"count":20,"type":21},6294,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, multicenter, prospective trial will enroll 6,294 participants in approximately 80 centers. STEMI patients with onset time within 12 hours and scheduled for primary PCI will be randomly assigned to two groups in a 1:1 ratio. Patients meeting the criteria were randomly assigned. It is recommended that loading doses of dual antiplatelet therapy be administered immediately after electrocardiogram diagnosis. The experimental group was required to be given an intravenous injection of 100 U\u002Fkg of UFH within 10 minutes after randomization, and this should be completed at least before delivery to the catheter lab. The control group was recommended to be given 100 U\u002Fkg of UFH through the arterial sheath, but the actual intraoperative dosage was determined by the interventional cardiologist. No patient is allowed to use low-molecular-weight heparin, bivalirudin, glycoprotein IIb\u002FIIIa inhibitors or other antithrombotic drugs before coronary angiography. The planned enrollment period for this study is 24 months. The scheduled follow-up visits will occur at 30 days (±7 days), 3 months (±14 days), and if conditions permit, at 6 months (±30 days) and 1 year (±30 days) after randomization. The purpose of this study is to evaluate the composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke within 30 days after randomization.",[27,28],"Primary PCI","ST-elevation Myocardial Infarction (STEMI)",[30,31,32],"Heparin","Primary Percutaneous Coronary Intervation","ST-Elevation Myocardial Infarction","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":37},"2026-01-25",{"date":41,"type":21},"2030-04-01",{"name":43,"class":44},"Chen Jing","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100638039","clonal-hematopoiesis-of-indeterminate-potential-and-infarct-severity-in-st-elevation-myocardial-infarction-100638039","NCT07615023","Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction","CHIP in STEMI","Inclusion Criteria:\n\n* Diagnosis of first acute ST-elevation myocardial infarction according to current European Society of Cardiology guidelines\n* Symptoms consistent with ST-elevation myocardial infarction lasting more than 30 minutes and less than 12 hours before primary percutaneous coronary intervention\n* Treatment with primary percutaneous coronary intervention\n* Age 18 to 75 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Prior myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention\n* Persistent hemodynamic instability, Killip class greater than 2 including cardiogenic shock, or resuscitated cardiac arrest not allowing cardiac magnetic resonance imaging\n* Known active or prior malignancy, including hematologic malignancies or myelodysplastic syndromes\n* Prior oncologic treatment with chemotherapy, radiotherapy, or radioisotopes\n* Abnormal baseline complete blood count with clinically significant cytopenia, defined as leukocytes less than 3.0 x 10\\^9\u002FL, platelets less than 100 x 10\\^9\u002FL, or hemoglobin less than 10 g\u002FdL\n* Chronic viral infection associated with systemic inflammation\n* Active autoimmune disease or chronic systemic inflammatory disorder\n* Chronic kidney disease with creatinine clearance less than 30 mL\u002Fmin\u002F1.73 m2\n* Contraindication to cardiac magnetic resonance imaging\n* Pre-ST-elevation myocardial infarction life expectancy of less than 1 year\n* Participation in an interventional trial\n* Limited possibility to attend follow-up examinations, for example residence abroad\n* Pregnancy",true,"75 Years",{"count":56,"type":21},350,"OBSERVATIONAL","Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the absence of a hematological malignancy. CHIP has been identified as an independent cardiovascular risk factor associated with increased rates of myocardial infarction, stroke, and cardiovascular mortality, likely mediated through enhanced inflammatory signaling in mutant macrophages and monocytes.\n\nST-elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate reperfusion by primary percutaneous coronary intervention (PCI). Despite successful reperfusion, adverse cardiac remodeling and heart failure may occur depending on myocardial injury severity, microvascular obstruction (MVO), and intramyocardial hemorrhage (IMH) - phenomena substantially driven by ischemia-reperfusion injury and the inflammatory response.\n\nThe CHIP in STEMI study is a prospective, observational, single-center cohort study at the Medical University of Innsbruck investigating whether CHIP - detected by targeted next-generation sequencing - is associated with greater infarct severity and worse cardiac outcomes in STEMI patients undergoing primary PCI. The primary endpoint is the presence of MVO and\u002For IMH on cardiac MRI (CMR) at 5±2 days post-PCI. Secondary endpoints include infarct size, left and right ventricular function, major adverse cardiovascular events (MACE), and immune cell transcriptome profiling by single-cell RNA sequencing.\n\n350 patients (18-75 years, minimum 90 female) will be enrolled over 36 months and followed for 4 years (2026-2030).",[28,60],"Clonal Hematopoiesis of Indeterminate Potential (CHIP)",[62,63,64,65],"CHIP","STEMI","cardiac MRI","microvascular obstruction","NOT_YET_RECRUITING","2026-05-22",{"date":69,"type":37},"2026-05-29",{"date":71,"type":21},"2026-06-20",{"date":73,"type":21},"2030-06-20",{"name":75,"class":44},"Medical University Innsbruck",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100606480","functional-milk-supplementation-to-reduce-in-stent-restenosis-in-stemi-patients-smasoea-trial-100606480","NCT07176104","Functional Milk Supplementation to Reduce In-Stent Restenosis in STEMI Patients (SMASOEA Trial)","Effects of Functional Bovine Milk Supplementation on Coronary In-Stent Restenosis and Major Adverse Cardiovascular Events in STEMI Patients Undergoing Primary PCI: A Randomized, Double-Blind, Controlled Trial","SMASOEA","Inclusion Criteria:\n\n* Age 18-80 years\n* First ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) and drug-eluting stent implantation within the previous 4 weeks\n* Stable clinical condition at enrollment\n* Willingness to adhere to study procedures and dietary supplementation for 12 months\n* Signed informed consent\n\nExclusion Criteria:\n\n* Previous myocardial infarction or coronary revascularization\n* Cardiogenic shock or severe heart failure (NYHA class IV)\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) or dialysis\n* Active malignancy or life expectancy \\\u003C1 year\n* Known lactose intolerance or allergy to milk proteins\n* Participation in another interventional clinical trial in the last 30 days","80 Years",{"count":86,"type":21},140,[24],"This randomized, double-blind, controlled clinical trial will evaluate the effects of daily supplementation with functionalized bovine milk, enriched with bioactive peptides and optimized lipid profile, on coronary in-stent restenosis and major adverse cardiovascular events (MACE) in patients with first ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) and drug-eluting stent (DES) implantation. Participants will be randomly assigned to receive either functionalized milk or an isocaloric non-functional milk for 12 months, in addition to standard secondary prevention care. The primary endpoint is the incidence of in-stent restenosis at 12 months, assessed by coronary computed tomography angiography (CCTA). Secondary endpoints include MACE occurrence, metabolic and inflammatory biomarkers, oxidative stress markers, serum sirtuins, metabolomic profiles, and myocardial injury evaluated by cardiac positron emission tomography (PET). The study aims to determine whether functionalized milk can improve cardiovascular outcomes and modulate pathophysiological mechanisms after STEMI.",[28,90],"In-stent Restenosis",[32,92],"Inflammation","2026-05-05",{"date":95,"type":37},"2026-05-06",{"date":97,"type":21},"2026-07",{"date":99,"type":21},"2027-08",{"name":101,"class":44},"Raffaele Marfella",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100573434","drug-eluting-balloon-or-drug-eluting-stent-in-acute-myocardial-infarction-a-randomized-controlled-trial-100573434","NCT06746233","Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial","A Prospective, Randomized, Multicenter, International, Open-Label Clinical Trial Comparing Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Acute ST-Elevation Myocardial Infarction.","BOOST-AMI","Inclusion Criteria:\n\n* Age \\>18 years with a life expectancy of \\>1 year;\n* Patients fulfilling criteria for STEMI (\\>20 min of chest-pain; At least 1 mm ST-elevation in at least two contiguous leads, a new left bundle branch block or a true posterior myocardial infarction confirmed by ECG or echocardiography; Reperfusion is expected to be feasible within 12 h after onset of symptoms)\n* Infarct related artery eligible for primary PCI (De novo lesion in a native coronary artery; Reference-vessel diameter ≥2.5 mm and ≤ 4 mm; Absence of severe calcification; Residual diameter stenosis of ≤30% (by visual assessment) after lesion preparation after lesion preparation; Absence of coronary dissection type ≥C.\n\nExclusion Criteria:\n\n* Killip class\\>II on admission\n* Known contraindication for aspirin, clopidogrel, ticagrelor, heparin or GP IIb\u002FIIIa inhibitor\n* Previous myocardial infarction\n* Previous PCI in the territory of the infarct-related artery (IRA)\n* Previous CABG\n* 3-vessel disease requiring revascularization\n* Left-main disease\n* Extremely angulated or severely calcified vessels\n* History of ischemic stroke within the past 6 months or hemorrhagic stroke\n* Planned CABG for a non-culprit vessel\n* Participation in another investigational trial that has not completed its primary endpoint or could interfere with the endpoints of this study",{"count":111,"type":21},598,[24],"The objective of the study is to compare drug-coated balloon (DCB) with the gold standard drug-eluting stent (DES) in percutaneous coronary intervention (PCI) for patients presenting with ST-elevation myocardial infarction (STEMI).\n\nRandomization will be performed after successful culprit-lesion preparation and confirmation that all angiographic entry criteria are met. Patients will be randomly assigned in a 1:1 fashion to receive either treatment with a Paclitaxel-coated balloon alone or second or third-generation DES.",[115],"ST Elevation Myocardial Infarction (STEMI)",[63,117,118],"DES","DCB","2026-03-25",{"date":121,"type":37},"2026-03-30",{"date":123,"type":37},"2024-12-25",{"date":125,"type":21},"2028-12",{"name":127,"class":44},"Institute of Cardiovascular Diseases, Vojvodina",5,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":57,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100629648","drug-coated-balloon-multicentric-registry-in-spain-and-portugal-100629648","NCT07477405","Drug-coatEd Balloon Multicentric Registry in Spain and PORTugal","DESPORT","Inclusion Criteria:\n\n1. Patient over the age of 18 years, undergoing PCI with at least one DCB attempted.\n2. Patient has provided written informed consent as approved by the Ethics Committee (EC)\n3. Patient is willing to undergo all registry procedures and follow-up requirements\n\nExclusion Criteria:\n\n1. Patients with known allergy to antiplatelet drugs or DCB antiproliferative agents\n2. Life expectancy less than 12 months\n3. Cardiogenic shock\n4. Left ventricular ejection fraction \\\u003C 15%.\n5. Any condition, which in the investigator opinion, would preclude safe participation of the patient in the registry.",{"count":137,"type":21},1200,"2 Years","Drug-eluting stents (DES) have been the main treatment option for coronary angioplasty (PCI) for many years. The antiproliferative drug in DES has the effect of preventing in-stent restenosis, which is typically a consequence of intimal hyperplasia, a characteristic phenomenon of bare metal stents (BMS).\n\nDES have shown to be safe and effective in many clinical and anatomical scenarios. There are, however, several caveats to DES, like restenosis, thrombosis, accelerated atherosclerosis, impossibility of surgical revascularization and disruption of vessel dynamics.\n\nThese phenomena have a very meaningful negative impact on patient outcomes. Drug-coated balloons (DCB) may avoid those limitations of DES and are an appealing alternative in many different scenarios. They have been the mainstay treatment of in-stent restenosis (ISR) and were formally recommended for this setting in internationally, although recent guidelines recommend DES over a DCB for a first DES restenosis. There is, however, solid evidence for their use in the context of any ISR (BMS or DES-related) and both comparing with POBA or DES. The presence of metal from previous stents makes the implantation of more stents even more of a thing to avoid.\n\nHigh bleeding risk may also be an advantageous setting for DCB, as it may allow for a shorter or less intensive anti-thrombotic treatment with the same or even improved safety endpoints when compared to BMS or DES with standard therapy.\n\nOther than ISR, there are other particularly appealing anatomical settings for DCBs such as bifurcations, small vessels and diffuse disease. In the setting of a bifurcation where only the side branch is to be treated, there is evidence that DCB is a good option and provides significantly less late luminal loss when compared to POBA. In case a stent is used in the main branch, a DCB is also a good option for the side branch.\n\nIn small vessels (\\\u003C3,0mm), in which the stent metal would be more conspicuous relative to the smaller lumen, there is strong evidence pointing to a benefit of DCB when compared to balloon angioplasty (POBA) and results at least as good as full-DES. A similar MACE rate between DCB and DES has been reported, with a benefit for DCB in terms of bleeding. In fact, also in larger vessels, DCB may lead to similarly good outcomes. DCB (alone or in combination with DES) is a good alternative to DES-only in diffuse disease.\n\nProvided that a good lesion preparation is achieved and there is no structural compromise to the vessel, the lack of a metal stent will be of benefit for any type of lesion. It will contribute to late lumen enlargement (LLE), which can happen in 40-56% of lesions treated with DCB7 and is associated with layered plaques by OCT and medial dissection after lesion preparation.\n\nEvidence for DCBs is increasing in different anatomical and clinical contexts, and there are some dedicated recommendations and consensus regarding their use. There is some data regarding real-world clinical performance of DCBs, but there is still the need for large real-world studies with different DCBs, techniques, clinical settings and anatomical contexts with long term follow-up, which is the main driver for this registry.",[141,28],"Coronary Artery Disease (CAD)",[143,144,145,146],"Drug-coated balloons","Percutaneous Coronary Intervention","DEB","PCI","2026-03-13",{"date":149,"type":37},"2026-03-17",{"date":151,"type":21},"2026-08-01",{"date":153,"type":21},"2029-12-30",{"name":155,"class":44},"Portuguese Association of Interventional Cardiology",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":45},"100625789","effect-of-digitally-supported-medical-nutrition-therapy-on-left-ventricular-ejection-fraction-in-patients-with-st-elevation-myocardial-infarction-100625789","NCT07427199","Effect of Digitally Supported Medical Nutrition Therapy on Left Ventricular Ejection Fraction in Patients With ST-Elevation Myocardial Infarction","Effect of Digitally Supported Medical Nutrition Therapy on Left Ventricular Ejection Fraction in Patients With ST-Elevation Myocardial Infarction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 19-65 who have fully completed the voluntary consent form\n* Being of normal weight (BMI 18.5-24.9 kg\u002Fm²) or obese (30-34.99 kg\u002Fm²)\n* Having suffered a heart attack with ST elevation (STEMI)\n* To be enrolled in the study within the first 72 hours after hospital admission\n* To be willing to participate in a follow-up period of at least 3 months\n\nExclusion Criteria:\n\n* Those who did not sign the voluntary consent form\n* Individuals aged over 65\n* Weight loss exceeding 5% in the last 3 months\n* Those with malignancy, chronic renal failure or severe systemic disease\n* Patients unable to complete the questionnaires due to severe cognitive impairment\n* Those who have previously received nutrition education or eating awareness training","19 Years","65 Years",{"count":166,"type":21},200,[24],"This study is designed to investigate the effect of a nutrition program supported by digital content on heart function in patients who have experienced a heart attack with ST-elevation. Participants will receive personalized dietary guidance and digital support materials for three months. The main goal is to determine whether this digital support materials can improve heart pumping function (measured by left ventricular ejection fraction). Participation involves following the dietary program and undergoing heart function measurements at the beginning, after one months and after three months.",[28],"2026-02-16",{"date":172,"type":37},"2026-02-23",{"date":174,"type":37},"2025-12-30",{"date":176,"type":21},"2026-12",{"name":178,"class":44},"Saglik Bilimleri Universitesi",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100573118","drug-coated-balloon-versus-drug-eluting-stent-in-patient-with-st-segment-elevation-myocardial-infarction-100573118","NCT06742125","Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction","DCB-STEMI","Inclusion Criteria:\n\n1. . Age of Patients ≥18 years old;\n2. Acute myocardial infarction patients with onset symptoms\\\u003C48 hours require emergency PCI;\n3. . Diagnosis: Chest pain and other ischemic symptoms accompanied by ST segment elevation in at least two adjacent leads on electrocardiogram (① V2 or V3 lead: male\\\u003C40 years ≥ 0.25mV, ≥ 40 years ≥ 0.2mV; Female ≥1.5mV；② Other leads ≥ 1mV), or new left bundle branch block occurs;\n4. Criminal blood vessels with clear requirements for emergency PCI;\n5. Coronary artery in situ lesions, with a visual reference lumen diameter of ≥ 2mm and ≤ 4mm; Lesion's length\\\u003C40mm；\n6. After thrombus aspiration and pre dilation, the lesion stenosis is ≤ 50% and there is no C-type or above dissection.\n7. He\u002Fshe or his\u002Fher legal representative voluntarily participates in this study and signs an informed consent form.\n\nExclusion Criteria:\n\n1. The patient has allergies or contraindications to the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Cilostazol, Indobufen, Contrast Medias (Patients with clear contrast agent allergies such as rash but can be controlled with effective drugs such as glucocorticoids and diphenhydramine in advance can be selected);\n2. The patient has active pathological bleeding;\n3. History of significant gastrointestinal or urogenital bleeding or bleeding tendency within 3 months prior to surgery, known coagulation disorders (including heparin induced thrombocytopenia);\n4. Patients who are pregnant or have the intention to become pregnant during the period of research;\n5. Non cardiogenic combined lesions show an expected life expectancy of less than one year;\n6. Left main trunk's stenosis ≥ 50%\n7. History of coronary artery bypass grafting in the past;\n8. Intubation or mechanical ventilation status;\n9. . Cardiogenic Shock\n10. . Without signature on informed consent",{"count":187,"type":21},1244,[24],"Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the \"leave-nothing-behind\" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.",[28],[192,193,194],"Drug-coated balloon","Drug-eluting stent","ST-elevation myocardial infarction (STEMI)","2026-01-27",{"date":197,"type":37},"2026-01-29",{"date":199,"type":37},"2025-05-31",{"date":201,"type":21},"2032-01-01",{"name":203,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":221,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":231,"locationsCount":45},"100559677","intracoronary-hypothermia-as-a-prevention-of-reperfusion-injury-in-myocardial-infarction-100559677","NCT06567249","Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.","Selective Intracoronary Hypothermia as a Prevention of Reperfusion Injury in ST-elevation Myocardial Infarction.","Inclusion Criteria:\n\n* Acute ST-elevation myocardial infarction\n* Time from onset of symptoms less than 12 hours\n* Given informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Cardiogenic shock\n* Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block.\n* Sick sinus syndrome requiring implantable pacemaker\n* Pulmonary edema\n* Active inflammatory condition\n* Active chemo\u002Fradiation therapy","90 Years",{"count":213,"type":21},60,[24],"Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.",[217,218,219,220],"Myocardial Infarction","ST-Elevation Myocardial Infarction (STEMI)","Reperfusion Injury","Microvascular Occlusion",[222,223,65,224,63],"hypothermia","ST-elevation myocardial infarction","reperfusion injury","2025-12-08",{"date":227,"type":37},"2025-12-16",{"date":229,"type":37},"2024-05-05",{"date":176,"type":21},{"name":232,"class":44},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":45},"100613307","for-patients-with-myocardial-infarction-and-multiple-vessel-testing-if-ultrasound-ufr-can-guide-all-needed-treatment-in-one-procedure-avoiding-a-return-hospital-visit-for-a-second-operation-100613307","NCT07264881","For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.","A Prospective, Longitudinal, Multi-modal Study Evaluating the Utility of Acute Phase UFR (IVUS-FFR) to Predict Functional Significance in the Stable Phase for Patients With Acute Coronary Syndrome (ACS)","ACT-EVOLVE","Inclusion Criteria:\n\n* Age \\>18 years, any sex.\n* The participant is able to understand the study procedures and provides voluntary written informed consent.\n* Diagnosed with Acute Coronary Syndrome (ACS) and meets the criteria for one of the two pre-specified cohorts:\n* STEMI Cohort: Symptom onset \\\u003C 12 hours with ECG findings of ST-segment elevation myocardial infarction.\n* High-Risk NSTEMI Cohort: Meets at least one of the following: GRACE score \\> 140, dynamic ECG changes (ST-T), or significant Troponin elevation.\n* Has undergone successful emergency PCI of the Culprit Vessel (CV), with post-PCI TIMI flow Grade 3.\n* Coronary angiography confirms Multi-vessel Disease (MVD), defined as: at least one Non-Culprit Vessel (NCV) with a moderate stenosis (visual diameter stenosis 50-90%).\n* The target NCV (50-90% stenosis) is deemed by the investigator to be anatomically suitable for IVUS and pressure-wire assessment.\n* The participant agrees and is confirmed to be willing and able to strictly adhere to the protocol and complete all required invasive procedures, CMR scans, and follow-ups at the four timepoints (T0, T-CMR, T1, T2).\n\nExclusion Criteria:\n\n* Presence of cardiogenic shock on presentation, or persistent hemodynamic instability despite successful PCI of the culprit vessel.\n* Known severe allergy to iodinated contrast media or gadolinium-based contrast agents (used for CMR).\n* Female participants who are pregnant, breastfeeding, or planning pregnancy within the 1-year study period.Unprotected left main coronary artery disease (stenosis \\\u003C50%) requiring intervention.\n* Prior history of Coronary Artery Bypass Grafting (CABG) surgery.The target NCV has received prior PCI (e.g., existing stent) or surgical revascularization.\n* The target NCV is a Chronic Total Occlusion (CTO).\n* Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m²) or currently undergoing chronic dialysis.\n* Standard contraindications to CMR examination (e.g., claustrophobia, non-MRI-compatible metallic implants\u002Fpacemakers).\n* Known presence of a severe non-cardiac comorbidity with an expected lifespan of \\\u003C 12 months (e.g., advanced malignancy).\n* Known severe hematological disease (e.g., severe anemia, active bleeding, thrombocytopenia \\\u003C 70 x 10⁹\u002FL) rendering the participant unsuitable for multiple invasive procedures.\n* Inability to provide informed consent or comply with the complex longitudinal follow-up protocol due to psychiatric, cognitive, or other reasons.\n* Currently participating in another interventional (drug or device) clinical study.\n* Any other condition which, in the investigator's opinion, makes the participant unsuitable for enrollment (e.g., severe valvular heart disease, cardiomyopathy).",{"count":166,"type":21},"Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable \"one-stop\" solution for treating heart attack patients who have multiple blocked arteries. Currently, doctors face a dilemma: Testing these other blockages during the heart attack procedure is often unreliable.\n\nThe most accurate method requires asking the patient to return 30 days later for a second invasive procedure, which is a significant burden.\n\nThe Study's Hypothesis : We are testing a new tool called UFR, which uses ultrasound images to measure blockages. Our hypothesis (or \"educated guess\") is that this new UFR tool is not affected by the body's stress during a heart attack and can provide a true, reliable measurement right away.\n\nThe Question the Study is Trying to Answer ： The main question this study is trying to answer is: Can the new \"one-stop\" UFR tool, used during the initial heart attack procedure, accurately predict which blockages are truly serious... thereby eliminating the need for patients to return for a second procedure 30 days later? Researchers will also follow 200 patients for one year, using advanced scans (like UFR, standard tests, and MRI), to better understand how the heart and arteries heal and change over time.",[244,245,246,115],"Microvascular Obstruction (MVO)","Multivessel Coronary Artery Disease","ACS (Acute Coronary Syndrome)",[248,249,250,251,252,253,254,255,256,257,258,259,260,261],"Acute Coronary Syndrome","Fractional Flow Reserve,","Intravascular Ultrasound","Virtual Fractional Flow Reserve","Functional Drift","Coronary Microvascular Dysfunction","Index of Microcirculatory Resistance","Non-Culprit Vessel","ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction","Cardiac Magnetic Resonance","Microvascular Obstruction","Staged Revascularization","Computational Fluid Dynamics","2025-11-24",{"date":264,"type":37},"2025-12-04",{"date":266,"type":21},"2025-12-02",{"date":268,"type":21},"2028-06-22",{"name":270,"class":44},"Beijing Anzhen Hospital",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":45},"100589603","platelet-derived-growth-factor-receptor--pdgfr-imaging-in-cardiac-fibrosis-100589603","NCT06956560","Platelet Derived Growth Factor Receptor ß (PDGFRß) Imaging in Cardiac Fibrosis","Microdosing, Non-randomized, Clinical Trial to Investigate Binding of Positron Emission Tomography Tracer [68ga]Ga-DOTA-Cys-ATH001 Targeting Platelet-derived Growth Factor Receptor Beta (PDGFRß) in Healthy Subject as Compared to Patients With Cardiac Fibrosis.","PARIS","Inclusion Criteria:\n\n* Willing and able to give written informed consent for participation in the trial and able to comply with all trial procedures and requirements.\n* Male or female participant aged 40 to 70 years, inclusive, at the screening visit.\n* Women of childbearing potential must practice abstinence from heterosexual intercourse or must agree to use a highly effective method of contraception.\n\nCohort-specific inclusion criteria:\n\nCohort 1, STEMI high-risk patients:\n\n* NT-proBNP \\>500 pg\u002FmL within 48 hrs after PCI\n* Post-PCI Thrombolysis In Myocardial Infarction (TIMI) score \\\u003C3.\n* No previous history of coronary artery disease or heart failure.\n\nCohort 2, STEMI low-risk patients\n\n* NT-proBNP \\\u003C500 pg\u002FmL within 48 hrs after PCI\n* Post-PCI TIMI score 3.\n* No previous history of coronary artery disease or heart failure.\n\nCohort 3 (HFpEF patients)\n\n* Presence of signs and symptoms of HF\n* Ejection Fraction ≥50%\n* Elevated levels of natriuretic peptides (NT-proBNP≥125pg\u002FmL)\n* At least one of the following:\n* Relevant structural heart disease (left ventricular hypertrophy or left atrial enlargement)\n* Diastolic dysfunction\n\nCohort 4 (healthy participants)\n\n* Individuals with no history of coronary disease or heart failure.\n* Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.\n\nExclusion Criteria:\n\n* Any contraindication for MRI according to a standard checklist\n* Having worked as a metal worker or welder.\n* Contraindication for gadolinium-based contrast agents such as risk of nephrogenic systemic fibrosis (NSF) or allergy to gadolinium.\n* Kidney dysfunction measured as estimated Glomerular filtration rate (eGFR)\\\u003C30 mL\u002Fmin\u002F1.73m2\n* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial or influence the results or the participant's ability to participate in the trial.\n* Any clinically significant illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the screening visit.\n* Any malignancy within the past 12 months before the screening visit, with the exception of successfully treated basal cell carcinoma of the skin or in situ prostate cancer under active surveillance, with no interventions scheduled during the period of trial participation.\n* Any active gastrointestinal hemorrhage in the past six months.\n* Acute or chronic disabling stroke.\n* Aortic aneurysm or aortic dissection.\n* Hypertensive crisis.\n* Circulatory unstable condition in need for mechanical support.\n* Any planned major surgery within the duration of the trial participation.\n* Participants who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.\n* Poor peripheral venous access, as judged by the Investigator.\n* The participant has any laboratory abnormality or condition that, in the Investigator's opinion, could adversely affect the safety of the participant or impair the assessment of trial results.\n* The participant is using any prohibited concomitant medications as described in the protocol, at the discretion of the Investigator.\n* The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.\n\nAdditional exclusion criteria for all participants (cohorts 1,2 and 4):\n\n* History of coronary artery disease or heart failure.","40 Years","70 Years",{"count":282,"type":21},30,"An observational, cross-sectional, longitudinal, microdosing Position Emission Tomography (PET) imaging study to investigate platelet derived growth factor receptor beta (PDGFRß) expression in the heart of patients with high or low risk of heart failure after a ST-Elevation Myocardial Infarction (STEMI) after a percutaneous coronary intervention (PCI) with a stent procedure, as well as in patients with heart failure with preserved ejection fraction (HFpEF) and healthy individuals.",[218,285],"Heart Failure With Preserved Ejection Fraction (HFpEF)","2025-08-04",{"date":288,"type":37},"2025-08-08",{"date":290,"type":37},"2025-06-01",{"date":176,"type":21},{"name":293,"class":44},"Uppsala University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100590254","microplastics-and-nanoplastics-mnps-in-patients-with-st-elevation-myocardial-infarction-stemi-100590254","NCT06965023","Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)","STEMI-Plastics","Inclusion Criteria:\n\nAll the following inclusion criteria should be fulfilled:\n\n1. Age \\> 18 years old;\n2. STEMI undergoing urgent invasive coronary angiography;\n3. Acute thrombotic coronary occlusion\u002Fsub-occlusion (TIMI 0\u002F1);\n4. Clinical indication to thromboaspiration;\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to percutaneous coronary intervention;\n2. Hemodynamic instability or cardiogenic shock;\n3. End-stage chronic kidney disease;\n4. Life expectancy \\\u003C 1 year due to non-cardiac pathology.",{"count":302,"type":21},130,"Air pollution and microplastics pose major public health threats. Emerging data have shown that micro- and nanoplastics (MNPs) are ubiquitous environmental pollutants accumulating in human tissues, triggering inflammation and prothrombotic state. This study will investigate the presence and burden of MNPs within coronary thrombi\u002Fthromboaspirate of patients presenting with ST segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and their association with cardiac damage, plaque vulnerability, microvascular obstruction, and cardiovascular events. Plaque vulnerability will be explored by optical coherence tomography, while microvascular obstruction will be assessed by bolus thermodilution and cardiac magnetic resonance. Participants will be followed up for 1-year to evaluate whether the presence and the burden of MNPs will be associated with a higher incidence of the cardiovascular events.",[28,305,306,307],"Microplastics","Nanoplastics","Pollution Exposure",[63,305,306,92,309,310,311,312,313,314,253,315,316],"OCT","Plaque composition","cardiac magnetic resonance","Pollution","Exposome","Infarct Size","IMR","MRR","2025-05-01",{"date":319,"type":37},"2025-05-11",{"date":321,"type":37},"2025-04-22",{"date":323,"type":21},"2027-12-31",{"name":325,"class":44},"Azienda Ospedaliera \"Sant'Andrea\"",10,{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100574258","phase-4-low-dose-evaluation-of-aspirin-after-stemi-patients-with-pci-a-multicenter-double-blind-randomized-controlled-clinical-trial-100574258","NCT06756945","Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial","LEAST","Inclusion Criteria:\n\nSTEMI patients with clear diagnosis Has received PCI treatment (at least the culprit's blood vessels have been treated); 18 years old and above, regardless of gender; Received DAPT upon discharge: aspirin+ticagrelor; Signed informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\nIndividuals with atrial fibrillation\u002FDVT\u002Fvalve surgery requiring anticoagulant medication; Combined cardiomyopathy (HCM\u002FDCM\u002FRCM); Combining severe ventricular arrhythmias requires ICD; Chronic obstructive pulmonary disease (bronchial asthma, chronic bronchitis, emphysema, pulmonary heart disease); Serious infectious diseases, including active hepatitis B, hepatitis C or AIDS patients; Diseases of the blood system, such as thrombocytopenia, severe anemia, leukemia, etc; Severe liver and kidney dysfunction; Malignant tumors; Cognitive impairment",{"count":335,"type":21},3612,[337],"PHASE4","The study aims to optimize the dual antiplatelet therapy regimen for patients with STEMI after PCI, focusing on addressing the following key technical challenges: establishing an effectiveness evaluation system for a low-dose aspirin (50mg\u002Fday) antithrombotic treatment strategy based on ticagrelor, including the formulation of a scientific non-inferiority margin, assessment criteria, and composite endpoint determination standards; constructing a strict risk assessment system for major bleeding events, including bleeding event grading based on BARC standards and a blind evaluation process by an independent endpoint event adjudication committee; and developing a quality control system for multicenter clinical research to ensure patient follow-up compliance and data reliability. By solving the above technical challenges, the study provides evidence-based medical support and technical support for optimizing the antithrombotic treatment regimen for STEMI patients after PCI.",[28],"2024-12-24",{"date":342,"type":37},"2025-01-03",{"date":344,"type":21},"2025-01",{"date":346,"type":21},"2027-12",{"name":270,"class":44}]